Issues
-
Cover Image
Cover Image
Gius and colleagues determined gene expression signatures of cervical carcinogenesis using cDNA microarrays to analyze RNA from laser-captured microdissected epithelium and underlying stroma from normal cervix, graded cervical intraepithelial neoplasia (CIN 1-3), cancer, and patient-matched normal cervical tissues. In this model, the CIN 1 transition coincides with a proproliferative/immunosuppression gene signature in the epithelium that probably represents the epithelial response to HPV infection. The CIN 2 transition coincides with a proangiogenic signature suggesting a cooperative signaling interaction between stroma and tumor cells. Finally, the CIN 3 and squamous cell carcinoma antigen transition coincide with a proinvasive gene signature that may be a response to epithelial tumor cell overcrowding. The yellow and red horizontal line in the middle of the figure represents the basement membrane that separates the epithelium and stromal compartments. Genes coded in dark red represent validated genes with increased expression whereas dark blue represents validated genes with decreased expression. Additional genes are also depicted in the model; gray signifies previously identified host and viral genes, and light red or light blue denotes genes that increase or decrease, respectively, from the microarray data but are not yet validated. For details, see the article by Gius and colleagues on page 7113 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Priority Reports
Metastasis-Associated Protein 1 Transgenic Mice: A New Model of Spontaneous B-Cell Lymphomas
Molecular Biology, Pathobiology, and Genetics
Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates
Cell, Tumor, and Stem Cell Biology
Nm23-H1 Suppresses Tumor Cell Motility by Down-regulating the Lysophosphatidic Acid Receptor EDG2
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption
Monoclonal Antibody Blockade of the Human Eag1 Potassium Channel Function Exerts Antitumor Activity
Immunology
Targeting Human γδ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer
Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice
Endocrinology
Clinical Research
Mouse Models of Prostate Adenocarcinoma with the Capacity to Monitor Spontaneous Carcinogenesis by Bioluminescence or Fluorescence
Epidemiology and Prevention
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.